ACIP immunization update

,

Practice Alert

ACIP immunization update

J Fam Pract. 2011 May;60(5):271-273

PDF Download

References

1. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years—United States, 2011. MMWR Morb Mortal Wkly Rep QuickGuide. 2011;60(5):1-4.

2. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States, 2011. MMWR Morb Mortal Wkly Rep. 2011;60(4):1-4.

3. Centers for Disease Control and Prevention. Pertussis (whooping cough): outbreaks. Available at: http://www.cdc.gov/pertussis/outbreaks.html. Accessed March 19, 2011.

4. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(1):13-15.

5. Centers for Disease Control and Prevention. ACIP presentation slides: February 2011 meeting. Available at www.cdc.gov/vaccines/recs/acip/slides-feb11.htm#pertussis. Accessed March 19, 2011.

6. Centers for Disease Control and Prevention. Recommended antimicrobial agents for treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. MMWR Recomm Rep. 2005;54(RR-14):1-16.

7. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.

8. Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1-18.

9. Campos-Outcalt D. Your guide to the new pneumococcal vaccine for children. J Fam Pract. 2010;59:394-398.

10. Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2011;60:72-76.

11. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:626-629.

More schedule details in the footnotes. The new schedules contain a number of clarifications in the footnotes that:^1,11

explain the spacing of the 3-dose primary series for hepatitis B vaccine (HepB) for infants if they do not receive a dose immediately after birth
clarify the circumstances in which children younger than age 9 need 2 doses of influenza vaccine
describe the availability of both a quadrivalent human papillomavirus vaccine (HPV4) and a bivalent vaccine (HPV2) to prevent precancerous cervical lesions and cancer
list the option for using HPV4 for males for the prevention of genital warts.

TABLE 2
Meningococcal conjugate vaccine recommendations by risk group, ACIP 2010

Risk group	Primary series	Booster dose
Individuals ages 11-18 years	1 dose, preferably at age 11 or 12 years	Age 16 years, if primary dose given at age 11 or 12 years Age 16-18 years, if primary dose given at age 13-15 years No booster needed if primary dose given at ≥16 years
HIV-infected individuals ages 11-18 years	2 doses, 2 months apart	Age 16 years, if primary series given at age 11 or 12 years Age 16-18 years, if primary series given at age 13-15 years No booster needed if primary series given at ≥16 years
Individuals ages 2-55 years with persistent complement component deficiency such as C5-C9, properdin, or factor D, or functional or anatomic asplenia	2 doses, 2 months apart	Every 5 years At the earliest opportunity if primary series was 1 dose, then every 5 years thereafter
Individuals ages 2-55 years with prolonged increased risk of exposure, such as microbiologists routinely working with Neisseria meningitidis and travelers to, or residents of, countries where meningococcal disease is hyperendemic or epidemic	1 dose	After 3 years for individuals ages 2-6 years After 5 years for individuals ≥7 years if still at increased risk
Source: Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2011.¹⁰

ACIP immunization update

References

Pages

Recommended Reading